Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Indo Amines Limited is a specialty chemicals manufacturer focused on aliphatic amines, amine derivatives, and specialty chemicals used in agrochemicals, pharmaceuticals, water treatment, and personal care applications. The company operates manufacturing facilities in India with export exposure to developed markets, competing on technical expertise in amine chemistry and cost-competitive production. Stock performance is driven by agrochemical demand cycles, raw material cost management (primarily ammonia and alcohols derived from natural gas/crude), and capacity utilization rates.
Indo Amines generates revenue by converting petrochemical feedstocks (ammonia, methanol, ethanol, higher alcohols) into value-added amine compounds through catalytic processes. Pricing power derives from technical service capabilities, regulatory compliance for pharmaceutical/agrochemical grades, and switching costs for customers requiring consistent quality specifications. Margins depend heavily on feedstock cost pass-through ability and capacity utilization - the company operates capital-intensive batch and continuous reactors with high fixed costs. Competitive advantage stems from established customer relationships in regulated end-markets, process know-how in amine chemistry, and cost position relative to Western producers.
Agrochemical industry demand cycles and inventory destocking/restocking by global crop protection companies
Ammonia and natural gas prices (primary feedstock costs representing 40-50% of COGS)
Capacity utilization rates at Indian manufacturing facilities and new capacity commissioning timelines
USD/INR exchange rate movements affecting export competitiveness and rupee-denominated earnings translation
Regulatory approvals for pharmaceutical-grade products and customer qualification timelines
Environmental regulations tightening globally for amine manufacturing (air emissions, wastewater treatment) requiring ongoing capex to maintain compliance and potentially disadvantaging smaller producers
Customer consolidation in agrochemical industry (mergers among crop protection companies) increasing buyer power and pricing pressure on intermediate suppliers
Shift toward bio-based and green chemistry alternatives in specialty chemicals, potentially displacing petrochemical-derived amines in certain applications over 5-10 year horizon
Chinese amine producers with lower cost structures and government support expanding capacity and competing aggressively on price in export markets
Backward integration by large agrochemical customers producing their own amine intermediates to secure supply and capture margins
Technology risk from competitors developing more efficient catalytic processes or continuous manufacturing techniques that lower production costs
Negative free cash flow of -$0.2B despite $0.7B operating cash flow indicates heavy capex cycle ($0.9B) that strains liquidity and increases reliance on external financing
Debt/Equity of 0.85x is manageable but limits financial flexibility if operating performance deteriorates or refinancing conditions tighten
Working capital intensity in chemical manufacturing (inventory, receivables) can consume cash during growth phases or if customers extend payment terms
moderate-to-high - Demand is tied to agricultural activity (weather patterns, crop prices, farmer economics) and industrial production in end-markets like water treatment and coatings. Agrochemical demand exhibits cyclicality based on global crop protection spending, which correlates with commodity crop prices and farmer profitability. Pharmaceutical applications provide some stability, but agrochemical exposure creates earnings volatility. Industrial production indices in key export markets (US, Europe, China) directly impact order flows.
Moderate impact through two channels: (1) Debt/Equity of 0.85x means financing costs affect profitability, though the 21.9% ROE suggests manageable leverage levels. Rising rates in India increase rupee borrowing costs for working capital and capex financing. (2) Higher global rates strengthen the USD, which benefits export competitiveness but may pressure customer demand in rate-sensitive end-markets. The negative FCF and $0.9B capex suggest ongoing capacity expansion requiring external financing, making the company sensitive to credit availability and cost.
Moderate - Chemical companies require trade credit for working capital (raw material purchases, customer payment terms). Tightening credit conditions in India or export markets could constrain growth. Customer credit quality matters given concentration in agrochemical sector, which has experienced financial stress among smaller players. The 1.27x current ratio indicates adequate short-term liquidity but limited buffer.
value - The stock trades at 0.7x Price/Sales and 8.1x EV/EBITDA, below typical specialty chemical multiples, suggesting value orientation. Recent underperformance (-24.2% over 6 months) despite 30.6% net income growth indicates market skepticism about sustainability or concerns about the capex cycle. The 21.9% ROE attracts investors seeking high returns on equity in cyclical industrials. Negative FCF yield (-2.6%) deters income-focused investors but may appeal to those betting on capacity expansion driving future cash generation. The combination of growth metrics (14.8% revenue growth, 29.2% EPS growth) at value multiples suggests a contrarian opportunity for investors willing to look through near-term execution risks.
high - Specialty chemical stocks exhibit elevated volatility due to commodity input cost swings, customer demand cyclicality, and operating leverage. The -14.1% three-month return demonstrates sensitivity to near-term sentiment shifts. Small-cap Indian chemical companies face additional volatility from currency fluctuations, domestic policy changes, and liquidity constraints. Beta likely exceeds 1.2x relative to broader Indian equity indices.